KalVista Pharmaceuticals (NASDAQ:KALV) Announces Quarterly Earnings Results

KalVista Pharmaceuticals (NASDAQ:KALV) posted its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.04, Yahoo Finance reports.

KalVista Pharmaceuticals Stock Performance

Shares of KALV opened at $12.87 on Friday. KalVista Pharmaceuticals has a 1 year low of $7.21 and a 1 year high of $16.88. The stock has a market capitalization of $542.96 million, a PE ratio of -3.79 and a beta of 0.91. The stock has a 50-day simple moving average of $13.16 and a 200-day simple moving average of $12.43.

Insider Buying and Selling

In related news, insider Paul K. Audhya sold 2,135 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the transaction, the insider now owns 83,745 shares in the company, valued at $1,038,438. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the completion of the transaction, the chief executive officer now directly owns 242,527 shares of the company’s stock, valued at approximately $2,912,749.27. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Paul K. Audhya sold 2,135 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $12.40, for a total value of $26,474.00. Following the sale, the insider now directly owns 83,745 shares in the company, valued at approximately $1,038,438. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,452 shares of company stock worth $282,491. Company insiders own 12.30% of the company’s stock.

Wall Street Analyst Weigh In

KALV has been the topic of a number of research analyst reports. Cantor Fitzgerald upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 26th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.